ASCO 2025
Advertisement
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Charles Rudin, MD, PhD, presented the data at the 2025 American Society of Clinical Oncology Annual Meeting.
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.